IBT is a Swedish limited liability company, whose B shares are listed on Nasdaq Stockholm. Control of the company is via the Annual General Meeting, the Board of Directors, the CEO and senior management in accordance with the Companies Act, rules of procedure for the Board and instructions for the President and the Swedish Code of Corporate Governance. The Board is responsible for evaluating the targets and for continuously evaluating IBTs financial position and results as well as evaluating the operational management.
IBT will provide information about any divergences from the Swedish Code of Corporate Governance in the Corporate Governance Report.
General Meetings
Nomination Committee
Board of Directors
Management Team
Internal Control
Articles of Association
Auditors
Whistleblowing
General Meetings
Annual General Meeting 2024
May 8 2024
IBT Announcement AGM 2024
Item 18 – The Board’s proposal for a resolution regarding implementation of an incentive program
IBT Remuneration Report 2023
IBT Auditors Report of Remuneration
Extraordinary Annual General Meeting 2023
June 9 2023
The Board of Directors’ report in accordance with Chapter 13 Section 6 of the Swedish Companies Act
Annual General Meeting 2023
May 8 2023
Item 19 – The Board’s proposal for a resolution regarding implementation of an incentive program
IBT – New Articles of Association
IBT Auditors Report of Remuneration
Annual General Meeting 2022
May 4 2022
Item 17 – The Board’s proposal for a resolution regarding implementation of an incentive program
Appendix A, Terms for warrants 2022-2025
IBT Auditors report remuneration
Annual General Meeting 2021
May 4 2021
Remuneration report – IBT 2020 ENG
Appendix 3 – Votes Cast AGM 2021 (SWE)
Annual General Meeting 2020
June 16, 2020
Board report on the evaluation of remuneration 2019
Appendix 4 Boards proposal warrant program
Annual General Meeting 2019
May 6, 2019
Additional documents
Board report on evaluation of remuneration 2018
Auditors report on remuneration 2018 (Swedish)
Annual General Meeting 2018
May 15, 2018
Additional documents
Board report on evaluation of remuneration
Extraordinary General Meeting
January 8, 2017
IBT EGM Minutes with Attachments (Swedish)
Annual General Meeting 2017
May 4, 2017
Additional documents
Proposal for Board Mandate Item 16
Nominating Committee
The 2023 Annual General Meeting resolved that the Chairman of the Board shall convene the three largest shareholders in the company in terms of voting rights, who may each appoint a member who, together with the Chairman of the Board, shall form the Nomination Committee. For the composition of the Nomination Committee, the ownership structure as of 30 June 2023 shall determine who are the largest shareholders in terms of voting rights. The member appointed by the largest shareholder in terms of voting rights on the Nomination Committee at that date shall be the Chairman of the Nomination Committee. If any of the three largest shareholders waives its right to appoint a member to the Nomination Committee, the next largest shareholder shall be given the opportunity to appoint a member to the Nomination Committee.
The Nomination Committee for the Annual General Meeting 2024 has been formed in accordance with the decision of the Annual General Meeting. The Nomination Committee consists of Per-Erik Andersson (Chairman of the Nomination Committee), appointed by the largest shareholder Annwall & Rothschild Investments AB, Sebastian Jahreskog, who through direct and indirect ownership is the company’s second largest shareholder, and Jannis Kitsakis, appointed by the third largest shareholder, Fjärde AP-fonden. In addition, Peter Rothschild is a member of the Nomination Committee in his capacity as Chairman of the Board.
Shareholders wishing to submit proposals to the Nomination Committee are welcome to contact the Chairman of the Nomination Committee by e-mail at pea@pealaw.se , phone, +46(0)70 537 98 92 or by letter:
Infant Bacterial Therapeutics AB
Att: Valberedningen
Bryggargatan 10
111 21 Stockholm, Sweden
The Nomination Committee for the Annual General Meeting 2024 has been formed in accordance with the decision of the Annual General Meeting. The Nomination Committee consists of Per-Erik Andersson (Chairman of the Nomination Committee), appointed by the largest shareholder Annwall & Rothschild Investments AB, Sebastian Jahreskog, who through direct and indirect ownership is the company’s second largest shareholder, and Jannis Kitsakis, appointed by the third largest shareholder, Fjärde AP-fonden. In addition, Peter Rothschild is a member of the Nomination Committee in his capacity as Chairman of the Board.
Shareholders wishing to submit proposals to the Nomination Committee are welcome to contact the Chairman of the Nomination Committee by e-mail at pea@pealaw.se , phone, +46(0)70 537 98 92 or by letter:
Infant Bacterial Therapeutics AB
Att: Valberedningen
Bryggargatan 10
111 21 Stockholm, Sweden
Internal Control
For later years (after 2018) refer to the respective annual report
Articles of Association
Articles of association for Infant Bacterial Therapeutics AB is available below in English and Swedish:
Auditor
The company’s auditors review the management and the CEO’s management of the company and the quality of the company’s financial reporting. The auditors also perform, on behalf of the Board, a review of the financial statements, including the year-end report, annual report review and review of a quarterly report.
The auditor’s report their audit to the shareholders through the audit report, which is presented at the Annual General Meeting.
The company’s auditor is Deloitte AB with Jenny Holmgren as auditor-in-charge.
Deloitte AB
Visiting address: Rehnsgatan 11, 113 79 Stockholm, Sweden
Telephone: +46 75 246 20 00
Whistleblowing
IBT strives to maintain a transparent business climate and high business ethics and we value the safety and respect of everyone affected by our business.
Our business principles are described in our sustainability policy. You have an important role in reporting your concern if you suspect any wrongdoing that is not in line with our sustainability policy. This gives IBT the possibility to prevent or correct any improper activity.
Staff as well as external parties may report suspected instances of violations against laws or unethical conduct through our whistleblower function.
If you feel you cannot be open with your identity, you are welcome to report your suspicions in a secure manner by using our whistleblowing service. You can report anonymously. There is no risk of reprisal due to reporting a violation. The service is managed by an external party: Advokatfirman Schjødt AS filial.
Reports are handled confidentially by Advokatfirman Schjødt AS filial. They forward filed reports directly to the board of directors of IBT, who determine how to deal with the report.
Reports may be made confidentially to: ibtherapeuticswhistleblower@schjodt.com
June 1, 2022
Infant Bacterial Therapeutics AB (publ)